| Literature DB >> 27133379 |
Dong Wu1, Guangpeng Zhou2, Peng Jin3, Jiqing Zhu4, Shijie Li5, Qi Wu5, Guiqi Wang4, Jianqiu Sheng3, Jianming Wang2, Lele Song2, Xiaoliang Han6, Jiaming Qian7.
Abstract
SEPT9 gene methylation was validated as a biomarker for colorectal cancer (CRC) for >10 years and available as the Epi proColon test as an aid in CRC detection for >6 years. It was proven to be an accurate, reliable, fast, and convenient molecular test. In this opportunistic screening study, we validated a further simplified SEPT9 gene methylation assay in 1031 subjects in Chinese hospitals. The sensitivity for CRC detection was 76.6% at a specificity of 95.9%, and the results showed a satisfactory detection rate for each CRC stage, including early stages. The new SEPT9 assay, with enhanced technical simplicity, convenience, and lower cost, did not differ in performance compared with Epi proColon 2.0, the commercialized SEPT9 assay. The CRC detection sensitivity was further enhanced when the assay was combined with carcinoembryonic antigen (sensitivity, 86.4%) or fecal immunochemical test (sensitivity, 94.4%), suggesting that the combined tests may be an effective option for future opportunistic screening. In brief, our study has validated a new SEPT9 assay and combined testing as an aid in cancer detection, providing a new approach for opportunistic CRC screening.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27133379 DOI： 10.1016/j.jmoldx.2016.02.005
Source DB: PubMed Journal: J Mol Diagn ISSN： 1525-1578 Impact factor: 5.568